Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Strategy

Set Alert for Strategy

Minoryx Preps For Tough Pricing Regime As CNS Orphan Drug Enters Phase II/III

Orphan drug development used to be considered a license to print money, with high price tags and a focused customer base. With the development of an increasingly tough orphan drug pricing environment in the US and Europe, biotechs are adopting new strategies. CNS drug developer Minoryx will introduce endpoints into its Phase II/III studies for rare brain disease X-ALD that should help demonstrate both efficacy and value for future pricing discussions.

Rare Diseases Research and Development Strategies Market Access
Advertisement

Strategy

Set Alert for Strategy

Latest From Strategy

Quick Commercial Standouts Lacking Among 2016 US Launches

The number of novel drugs approved by FDA in 2016 was down versus prior years, and many of the drugs that did launch are off to a slow start. The expectation is increasingly for drugs to build sales over time.

Launches Commercial

BMS M&A Q&A: Is IO Player Now In Play? Lung Cancer Moves Seen As Key

Will activist investors succeed in unlocking Bristol-Myers Squibb's shareholder value - or instead orchestrate a takeover worth more than $100bn?

M & A Strategy

Hemophilia: How To Please Payers And Secure Market Share

Pharma companies are bringing forward innovative products that are set to shake up the hemophilia market – but convincing payers that they have substantial benefits over the current standards of care will be a challenge. Real-world data and early conversations with payers will be key, new research has found.

Rare Diseases Private Payers

Sumitomo Dainippon Shores Business/Pipeline Ahead Of Latuda Cliff

Facing the looming loss of exclusivity for its top product, Sumitomo Dainippon Pharma is looking to its late-stage pipeline and recent product and corporate acquisitions to help plug the hole.

Commercial Strategy

Mylan’s Growth Strategy: Diversification, Expansion And R&D Investment

The generic drug company will drive mid-term growth by investing in high-barrier-to-entry generics and biosimilars while diversifying into brand medicines and over-the-counter drugs. Management presented a strategy overview during an investor day March 1.

Biosimilars Business Strategies

Finance Watch: Surrozen Raises $33m In $483m February Flurry; Also, Are Reverse Mergers This Year's IPOs?

Surrozen raised $33m to fund drug development programs targeting Wnt ligands for various indications during a February VC financing flurry that occurred despite a drop in IPOs. Taking an alternative route to going public, some biopharma companies have completed reverse mergers in recent weeks and months.

Financing StartUps and SMEs
See All
UsernamePublicRestriction

Register